Cargando…

The effect of oral dabigatran etexilate on bone density, strength, and microstructure in healthy mice

Thrombin is a key component in the coagulation cascade where it converts factor V, VIII, XI, and fibrinogen. In addition to the abundant production of thrombin in the liver, osteoclasts synthesize and secrete thrombin as well. Osteoblasts express thrombin receptors, and it has been reported that thr...

Descripción completa

Detalles Bibliográficos
Autores principales: Brent, Mikkel Bo, Thomsen, Jesper Skovhus, Brüel, Annemarie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021300/
https://www.ncbi.nlm.nih.gov/pubmed/29963600
http://dx.doi.org/10.1016/j.bonr.2017.12.001
_version_ 1783335439502934016
author Brent, Mikkel Bo
Thomsen, Jesper Skovhus
Brüel, Annemarie
author_facet Brent, Mikkel Bo
Thomsen, Jesper Skovhus
Brüel, Annemarie
author_sort Brent, Mikkel Bo
collection PubMed
description Thrombin is a key component in the coagulation cascade where it converts factor V, VIII, XI, and fibrinogen. In addition to the abundant production of thrombin in the liver, osteoclasts synthesize and secrete thrombin as well. Osteoblasts express thrombin receptors, and it has been reported that thrombin stimulates the expression of RANKL relatively to OPG, resulting in greater osteoclast activation and bone degradation. Pradaxa (dabigatran etexilate, DE) is a new anticoagulant, which has recently been approved for clinical use. DE is a direct thrombin inhibitor with potential to modulate the RANKL/OPG ratio and thereby limit osteoclast activation and bone degradation. The purpose of the study was to investigate whether DE can increase bone density, bone strength, and bone microstructure in healthy male and female mice and to investigate whether the effect of DE is sex-dependent. Twenty-eight 14-week-old male C57BL/6 mice were stratified by weight into 4 groups: 1. Control 3 weeks; 2. DE 3 weeks; 3. Control 6 weeks; 4. DE 6 weeks. An identical study design was applied to twenty-four 14-week-old female C57BL/6 mice. Chow mixed with DE was offered ad libitum, resulting in a dose of 1.70 mg DE/g body weight and 1.52 mg DE/g body weight, to female and male mice, respectively. The animals were euthanized after 3 or 6 weeks. Bone mineral density (aBMD) and bone mineral content (BMC) were evaluated with DEXA, 3D microstructural properties were determined with μCT, bone strength was determined with mechanical testing, and bone formation and resorption was evaluated with bone histomorphometry. In female mice, DE resulted in significant higher tibial aBMD values after 6 weeks of intervention. Furthermore, DE significantly increased tibial diaphyseal cortical bone area and tissue area, which was accompanied by significantly increased strength of the tibial shaft. DE had no effect on femoral cortical bone or on femoral and vertebral trabecular 3D microstructure. Finally, bone histomorphometry showed that DE had no effect on MS/BS or Oc.S/BS. In male mice, no bone positive effects of DE were found in any of the parameters investigated. In conclusion, intervention with DE may result in a weak positive site specific effect at tibial cortical bone in female mice, and importantly, no major deleterious effects of DE on bone tissue were seen in either female or male mice despite the relatively high dose of DE used.
format Online
Article
Text
id pubmed-6021300
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-60213002018-06-29 The effect of oral dabigatran etexilate on bone density, strength, and microstructure in healthy mice Brent, Mikkel Bo Thomsen, Jesper Skovhus Brüel, Annemarie Bone Rep Article Thrombin is a key component in the coagulation cascade where it converts factor V, VIII, XI, and fibrinogen. In addition to the abundant production of thrombin in the liver, osteoclasts synthesize and secrete thrombin as well. Osteoblasts express thrombin receptors, and it has been reported that thrombin stimulates the expression of RANKL relatively to OPG, resulting in greater osteoclast activation and bone degradation. Pradaxa (dabigatran etexilate, DE) is a new anticoagulant, which has recently been approved for clinical use. DE is a direct thrombin inhibitor with potential to modulate the RANKL/OPG ratio and thereby limit osteoclast activation and bone degradation. The purpose of the study was to investigate whether DE can increase bone density, bone strength, and bone microstructure in healthy male and female mice and to investigate whether the effect of DE is sex-dependent. Twenty-eight 14-week-old male C57BL/6 mice were stratified by weight into 4 groups: 1. Control 3 weeks; 2. DE 3 weeks; 3. Control 6 weeks; 4. DE 6 weeks. An identical study design was applied to twenty-four 14-week-old female C57BL/6 mice. Chow mixed with DE was offered ad libitum, resulting in a dose of 1.70 mg DE/g body weight and 1.52 mg DE/g body weight, to female and male mice, respectively. The animals were euthanized after 3 or 6 weeks. Bone mineral density (aBMD) and bone mineral content (BMC) were evaluated with DEXA, 3D microstructural properties were determined with μCT, bone strength was determined with mechanical testing, and bone formation and resorption was evaluated with bone histomorphometry. In female mice, DE resulted in significant higher tibial aBMD values after 6 weeks of intervention. Furthermore, DE significantly increased tibial diaphyseal cortical bone area and tissue area, which was accompanied by significantly increased strength of the tibial shaft. DE had no effect on femoral cortical bone or on femoral and vertebral trabecular 3D microstructure. Finally, bone histomorphometry showed that DE had no effect on MS/BS or Oc.S/BS. In male mice, no bone positive effects of DE were found in any of the parameters investigated. In conclusion, intervention with DE may result in a weak positive site specific effect at tibial cortical bone in female mice, and importantly, no major deleterious effects of DE on bone tissue were seen in either female or male mice despite the relatively high dose of DE used. Elsevier 2017-12-18 /pmc/articles/PMC6021300/ /pubmed/29963600 http://dx.doi.org/10.1016/j.bonr.2017.12.001 Text en © 2017 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Brent, Mikkel Bo
Thomsen, Jesper Skovhus
Brüel, Annemarie
The effect of oral dabigatran etexilate on bone density, strength, and microstructure in healthy mice
title The effect of oral dabigatran etexilate on bone density, strength, and microstructure in healthy mice
title_full The effect of oral dabigatran etexilate on bone density, strength, and microstructure in healthy mice
title_fullStr The effect of oral dabigatran etexilate on bone density, strength, and microstructure in healthy mice
title_full_unstemmed The effect of oral dabigatran etexilate on bone density, strength, and microstructure in healthy mice
title_short The effect of oral dabigatran etexilate on bone density, strength, and microstructure in healthy mice
title_sort effect of oral dabigatran etexilate on bone density, strength, and microstructure in healthy mice
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021300/
https://www.ncbi.nlm.nih.gov/pubmed/29963600
http://dx.doi.org/10.1016/j.bonr.2017.12.001
work_keys_str_mv AT brentmikkelbo theeffectoforaldabigatranetexilateonbonedensitystrengthandmicrostructureinhealthymice
AT thomsenjesperskovhus theeffectoforaldabigatranetexilateonbonedensitystrengthandmicrostructureinhealthymice
AT bruelannemarie theeffectoforaldabigatranetexilateonbonedensitystrengthandmicrostructureinhealthymice
AT brentmikkelbo effectoforaldabigatranetexilateonbonedensitystrengthandmicrostructureinhealthymice
AT thomsenjesperskovhus effectoforaldabigatranetexilateonbonedensitystrengthandmicrostructureinhealthymice
AT bruelannemarie effectoforaldabigatranetexilateonbonedensitystrengthandmicrostructureinhealthymice